奥拉西坦对脑卒中后认知功能障碍患者认知功能的影响  

Effect of oxiracetam on cognitive function of patients with cognitive dysfunction after stroke

作　　者：卞光亮[1] 张茜[2] BIAN Guangliang;ZHANG Qian(Department of Medical Insurance,The Second People's Hospital of Lianyungang City,Lianyungang,Jiangsu,222006;Department of Pharmacy,The Second People's Hospital of Lianyungang City,Lianyungang,Jiangsu,222006)

机构地区：[1]江苏省连云港市第二人民医院医保处,江苏连云港222006 [2]江苏省连云港市第二人民医院药剂科,江苏连云港222006

出　　处：《实用临床医药杂志》2020年第16期29-31,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨奥拉西坦对脑卒中后认知功能障碍患者认知功能的影响。方法选取87例脑卒中后认知功能障碍患者,应用盲抽法分为对照组(n=43)与观察组(n=44)。对照组给予吡拉西坦治疗,观察组给予奥拉西坦治疗,比较2组临床疗效、认知功能、细胞因子水平及不良反应发生率。结果对照组总有效率为79.07%,低于观察组的95.45%,差异有统计学意义(P<0.05)。治疗后,2组简易智力状况检查量表(MMSE)评分均较治疗前提高,且观察组高于对照组,差异均有统计学意义(P<0.05)。治疗后,2组基质金属蛋白酶-3(MMP-3)、丙二醛(MDA)水平较治疗前降低,超氧化物歧化酶(SOD)水平较治疗前升高,且观察组MMP-3、MDA水平低于对照组,SOD水平高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为6.82%,对照组为13.95%,差异无统计学意义(P>0.05)。结论脑卒中后认知功能障碍患者采用奥拉西坦治疗效果显著,可有效改善机体细胞因子水平和患者认知功能,且安全性高。Objective To investigate the effect of oxiracetam on cognitive function of patients with cognition dysfunction after stroke.Methods Totally 87 patients with cognition dysfunction after stroke were divided into control group(n=43)and observation group(n=44)according to blind selection method.The control group was treated with piracetam,and the observation group was treated with oxiracetam.The clinical efficacy,cognitive function,levels of cytokines and the incidence of adverse reactions were compared between two groups.Results The total effective rate of the control group was 79.07%,which was significantly lower than 95.45%of the observation group(P<0.05).After treatment,the scores of Mini-mental State Examination(MMSE)in both groups were significantly higher than those before treatment,and the score of MMSE in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the levels of matrix metalloproteinase-3(MMP-3)and malondialdehyde(MDA)in both groups were significantly lower than those before treatment,the level of superoxide dismutase(SOD)was significantly higher than that before treatment,the levels of MMP-3 and MDA in the observation group were significantly lower than those in the control group,and the level of SOD in the observation group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 6.82%,which showed no significant difference when compared to 13.95% in the control group(P>0.05).Conclusion Oxiracetam is effective in the treatment of patients with cognitive dysfunction after stroke,which can effectively improve the cytokines level and cognitive function and it has a higher safety.

关 键 词：脑卒中 认知功能障碍 奥拉西坦 基质金属蛋白酶 超氧化物歧化酶 

分 类 号：R743.3[医药卫生—神经病学与精神病学]